Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Bladder Cancer

  Free Subscription


17.06.2024

1 Abdom Radiol (NY)
1 ACS Nano
1 Altern Ther Health Med
1 Am J Cancer Res
1 Am Soc Clin Oncol Educ Book
1 Ann Surg Oncol
1 Arch Gynecol Obstet
2 Biochem Genet
1 BJUI Compass
1 BMC Cancer
1 BMC Ophthalmol
1 BMC Urol
1 BMJ Open
1 Cancer Biol Ther
1 Clin Transl Oncol
1 Diagn Pathol
1 Eur J Med Res
2 Eur Urol Focus
1 Eur Urol Oncol
1 Expert Opin Biol Ther
1 Front Artif Intell
2 Front Oncol
1 Front Pharmacol
1 Future Oncol
1 Gene
1 Heliyon
1 Hum Pathol
1 Insights Imaging
1 Int J Biol Markers
1 Int J Surg
1 Iran Biomed J
1 J Asian Nat Prod Res
1 J Magn Reson Imaging
1 J Oncol Pharm Pract
1 J Pathol
5 J Urol
1 JCO Precis Oncol
2 Mol Oncol
1 Rev Med Liege
1 Sci Rep
1 Toxicol In Vitro
1 Transl Androl Urol
1 Urologia
5 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Abdom Radiol (NY)

  1. KONG L, Ling J, Cao W, Wen Z, et al
    Multiparametric MR characterization for human epithelial growth factor receptor 2 expression in bladder cancer: an exploratory study.
    Abdom Radiol (NY). 2024 Jun 13. doi: 10.1007/s00261-024-04378.
    PubMed         Abstract available


    ACS Nano

  2. LI Q, Zhan S, Yang X, Zhang Z, et al
    Choline Phosphate-Grafted Nanozymes as Universal Extracellular Vesicle Probes for Bladder Cancer Detection.
    ACS Nano. 2024 Jun 10. doi: 10.1021/acsnano.4c00280.
    PubMed         Abstract available


    Altern Ther Health Med

  3. FENG K
    Effectiveness of Comprehensive Nursing Intervention Based on the Roy Adaptation Model in the Perioperative Period of Bladder Cancer.
    Altern Ther Health Med. 2024 Jun 14:AT10139.
    PubMed         Abstract available


    Am J Cancer Res

  4. JIANG J, Xu J, Ou L, Yin C, et al
    ITM2A inhibits the progression of bladder cancer by downregulating the phosphorylation of STAT3.
    Am J Cancer Res. 2024;14:2202-2215.
    PubMed         Abstract available


    Am Soc Clin Oncol Educ Book

  5. VLACHOU E, Johnson BA 3rd, Baraban E, Nadal R, et al
    Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer.
    Am Soc Clin Oncol Educ Book. 2024;44:e438640.
    PubMed         Abstract available


    Ann Surg Oncol

  6. SONG W, Yu J, Chung JH, Kang M, et al
    A Proposal for Standardization of Early Outcomes Following Robot-Assisted Radical Cystectomy (RARC): RARC Tetrafecta.
    Ann Surg Oncol. 2024;31:4752-4761.
    PubMed         Abstract available


    Arch Gynecol Obstet

  7. SCHRODER C, Ploger R, Knupfer S, Tascon Padron L, et al
    Anterior enterocele after cystectomy: case report and review of the literature.
    Arch Gynecol Obstet. 2024;310:11-21.
    PubMed         Abstract available


    Biochem Genet

  8. CHI Q, Wang Z, Xu H, Li H, et al
    Circ_0000758 Facilitates Bladder Cancer Cell Growth, Migration and Angiogenesis Via Severing as miR-1236-3p Sponge.
    Biochem Genet. 2024 Jun 13. doi: 10.1007/s10528-024-10855.
    PubMed         Abstract available

  9. ZHANG P, Song D, Fang Z, Sun D, et al
    Cardamomin Inhibits the Proliferation and Tumorigenesis of Bladder Cancer by ESR1 in PI3K/AKT Pathway.
    Biochem Genet. 2024 Jun 12. doi: 10.1007/s10528-024-10854.
    PubMed         Abstract available


    BJUI Compass

  10. LAHOUD J, Patel MI, Naher S, Mercieca-Bebber R, et al
    A systematic review of the patient reported outcomes that affect patients with muscle invasive bladder cancer after radical cystectomy and urinary diversion.
    BJUI Compass. 2024;5:524-540.
    PubMed         Abstract available


    BMC Cancer

  11. JI J, Zhang T, Zhu L, Yao Y, et al
    Using machine learning to develop preoperative model for lymph node metastasis in patients with bladder urothelial carcinoma.
    BMC Cancer. 2024;24:725.
    PubMed         Abstract available


    BMC Ophthalmol

  12. WANG JN, Zhang Y, Huang CY, Li K, et al
    Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
    BMC Ophthalmol. 2024;24:240.
    PubMed         Abstract available


    BMC Urol

  13. ZAREINEJAD M, Faghih Z, Ramezani A, Safaei A, et al
    Exploring heterogeneous expression of beta-actin (ACTB) in bladder cancer by producing a monoclonal antibody 6D6.
    BMC Urol. 2024;24:124.
    PubMed         Abstract available


    BMJ Open

  14. REZAEE ME, Mahon KM, Trock BJ, Nguyen TE, et al
    ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol.
    BMJ Open. 2024;14:e076763.
    PubMed         Abstract available


    Cancer Biol Ther

  15. HUANG J, Michaud E, Shinde-Jadhav S, Fehric S, et al
    Effects of combined radiotherapy with immune checkpoint blockade on immunological memory in luminal-like subtype murine bladder cancer model.
    Cancer Biol Ther. 2024;25:2365452.
    PubMed         Abstract available


    Clin Transl Oncol

  16. COELHO JQ, Ramos MJ, Ranchor R, Pichel R, et al
    What's new about the tumor microenvironment of urothelial carcinoma?
    Clin Transl Oncol. 2024;26:1549-1560.
    PubMed         Abstract available


    Diagn Pathol

  17. FAHOUM I, Tsuriel S, Rattner D, Greenberg A, et al
    Automatic analysis of nuclear features reveals a non-tumoral predictor of tumor grade in bladder cancer.
    Diagn Pathol. 2024;19:75.
    PubMed         Abstract available


    Eur J Med Res

  18. DU L, Wang B, Wen J, Zhang N, et al
    No causal association between insomnia and bladder cancer: a bidirectional two-sample Mendelian randomization study.
    Eur J Med Res. 2024;29:316.
    PubMed         Abstract available


    Eur Urol Focus

  19. MCINERNEY S, Jones RJ
    Toxicities of Novel Agents for the Treatment of Advanced Bladder Cancer.
    Eur Urol Focus. 2024 Jun 7:S2405-4569(24)00075-0. doi: 10.1016/j.euf.2024.
    PubMed         Abstract available

  20. DAY E, Gavira J, Tapia JC, Anguera G, et al
    What About Variant Histologies in Bladder Cancer?
    Eur Urol Focus. 2024 Jun 6:S2405-4569(24)00078-6. doi: 10.1016/j.euf.2024.
    PubMed         Abstract available


    Eur Urol Oncol

  21. GUERRERO-RAMOS F, Boormans JL, Daneshmand S, Gontero P, et al
    Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2024 Jun 6:S2588-9311(24)00143-3. doi: 10.1016/j.euo.2024.
    PubMed         Abstract available


    Expert Opin Biol Ther

  22. KHENE ZE, Lotan Y
    An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer.
    Expert Opin Biol Ther. 2024 Jun 13:1-9. doi: 10.1080/14712598.2024.2365802.
    PubMed         Abstract available


    Front Artif Intell

  23. BORNA MR, Sepehri MM, Shadpour P, Khaleghi Mehr F, et al
    Enhancing bladder cancer diagnosis through transitional cell carcinoma polyp detection and segmentation: an artificial intelligence powered deep learning solution.
    Front Artif Intell. 2024;7:1406806.
    PubMed         Abstract available


    Front Oncol

  24. POON DMC, Ho LY, Kwong YM
    Avelumab maintenance therapy for node-positive muscle invasive bladder cancer: a report of two cases.
    Front Oncol. 2024;14:1397738.
    PubMed         Abstract available

  25. UYSAL D, Thaqi B, Fierek A, Jurgowski D, et al
    Prognostic significance of EGFR, AREG and EREG amplification and gene expression in muscle invasive bladder cancer.
    Front Oncol. 2024;14:1370303.
    PubMed         Abstract available


    Front Pharmacol

  26. PENG X, Liu C, Zhang L, Chen Y, et al
    IL4I1: a novel molecular biomarker represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Front Pharmacol. 2024;15:1365683.
    PubMed         Abstract available


    Future Oncol

  27. YOO C, Lamarca A, Choi HJ, Vogel A, et al
    Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors.
    Future Oncol. 2024;20:1069-1077.
    PubMed         Abstract available


    Gene

  28. ZHOU R, Zhou J, Deng S, Zhu Y, et al
    Developing and experimental validating a B cell exhaustion-related gene signature to assess prognosis and immunotherapeutic response in bladder cancer.
    Gene. 2024;927:148634.
    PubMed         Abstract available


    Heliyon

  29. YANG Z, Li X, Zhou L, Luo Y, et al
    Ferroptosis-related lncRNAs: Distinguishing heterogeneity of the tumour microenvironment and predicting immunotherapy response in bladder cancer.
    Heliyon. 2024;10:e32018.
    PubMed         Abstract available


    Hum Pathol

  30. ZHENG L, Chen H, Zhao J, Roy-Chowdhuri S, et al
    Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases.
    Hum Pathol. 2024;148:1-6.
    PubMed         Abstract available


    Insights Imaging

  31. FAN Z, Guo J, Zhang X, Chen Z, et al
    Non-Gaussian diffusion metrics with whole-tumor histogram analysis for bladder cancer diagnosis: muscle invasion and histological grade.
    Insights Imaging. 2024;15:138.
    PubMed         Abstract available


    Int J Biol Markers

  32. WANG X, Zhang S, Sun Y, Cai L, et al
    The prognostic significance of preoperative platelet-to-lymphocyte ratio and interleukin-6 level in non-muscle invasive bladder cancer.
    Int J Biol Markers. 2024 Jun 11:3936155241261719. doi: 10.1177/03936155241261719
    PubMed         Abstract available


    Int J Surg

  33. ZHU X, He J, Chen J
    A commentary on "Genetically proxied intestinal microbiota and risk of bladder cancer".
    Int J Surg. 2024 Jun 10. doi: 10.1097/JS9.0000000000001780.
    PubMed        


    Iran Biomed J

  34. ALBADAWY A, Alqudaimi M, Cui H, Yan X, et al
    Identification of Hydroxysteroid Dehydrogenase Type 1 As a Potential Bladder Tumor Marker.
    Iran Biomed J. 2024;28.
    PubMed         Abstract available


    J Asian Nat Prod Res

  35. ZHAI Z, Fu J, Ye ML, Wang JY, et al
    The changes of intestinal microbiota and metabolomics during the inhibition of bladder cancer by liquiritigenin.
    J Asian Nat Prod Res. 2024 Jun 13:1-10. doi: 10.1080/10286020.2024.2366010.
    PubMed         Abstract available


    J Magn Reson Imaging

  36. LI J
    Editorial for "Amide Proton Transfer-Weighted Imaging in Assessing the Aggressive and Proliferative Potential of Bladder Cancer".
    J Magn Reson Imaging. 2024 Jun 13. doi: 10.1002/jmri.29468.
    PubMed        


    J Oncol Pharm Pract

  37. KHOSLA H, Bhatt S, Wang MJ, Gignac G, et al
    Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
    J Oncol Pharm Pract. 2024;30:941-944.
    PubMed         Abstract available


    J Pathol

  38. VANGURI RS, Smithy JW, Li Y, Zhuang M, et al
    Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
    J Pathol. 2023;261:349-360.
    PubMed         Abstract available


    J Urol

  39. CHANG SS
    Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
    J Urol. 2024 Apr 22:101097JU0000000000003900. doi: 10.1097/JU.0000000000003900.
    PubMed        

  40. PATEL SH, Gabrielson AT, Chan S, Schwartz D, et al
    A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guerin?Naive Nonmuscle-Invasive Urothelial Carcinoma of the Bladder.
    J Urol. 2024;212:95-103.
    PubMed         Abstract available

  41. LOTAN Y, Daneshmand S, Shore N, Black P, et al
    A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial.
    J Urol. 2024;212:41-51.
    PubMed         Abstract available

  42. LAZAROVICH A, Dahmen AS, Modi PK, Agarawal PK, et al
    Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
    J Urol. 2024;212:236-237.
    PubMed        

  43. KASEB H, Leslie SW, Soon-Sutton TL, Aeddula NR, et al
    The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Guerin in Treating Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2024 Jun 7:101097JU0000000000004070. doi: 10.1097/JU.0000000000004070.
    PubMed         Abstract available


    JCO Precis Oncol

  44. SATYAL U, Valentine H, Liu D, Slifker M, et al
    Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates.
    JCO Precis Oncol. 2024;8:e2300362.
    PubMed         Abstract available


    Mol Oncol

  45. KAWAHARA I, Yoshino H, Fukumoto W, Arima J, et al
    Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models.
    Mol Oncol. 2024 Jun 14. doi: 10.1002/1878-0261.13684.
    PubMed         Abstract available

  46. LAMMERT FC, Pannhausen J, Noetzel E, Friedland F, et al
    Dual role of GRHL3 in bladder carcinogenesis depending on histological subtypes.
    Mol Oncol. 2024;18:1397-1416.
    PubMed         Abstract available


    Rev Med Liege

  47. DUCHENE L, Davenne E, Lifrange F, Detrembleur N, et al
    [Urinary cytology for the detection of urothelial lesions].
    Rev Med Liege. 2024;79.
    PubMed         Abstract available


    Sci Rep

  48. LUO J, Luo F, Li Q, Liu Q, et al
    An immunogenic cell death-related lncRNA signature correlates with prognosis and tumor immune microenvironment in bladder cancer.
    Sci Rep. 2024;14:13106.
    PubMed         Abstract available


    Toxicol In Vitro

  49. ZHANG G, Wei W, Li S, Yang J, et al
    Transcription Factor yin-Yang 1 augments nucleoporin 93 oncogene activity and modulates bladder Cancer malignancy.
    Toxicol In Vitro. 2024 Jun 8:105875. doi: 10.1016/j.tiv.2024.105875.
    PubMed         Abstract available


    Transl Androl Urol

  50. FANG K, Fang DL, Yu H, Chen YA, et al
    Exploring the microRNA-mRNA regulatory network associated with solasonine in bladder cancer.
    Transl Androl Urol. 2024;13:812-827.
    PubMed         Abstract available


    Urologia

  51. PAKMANESH H, Khajehsalimi A, Hesamarefi M, Ebadzadeh MR, et al
    Comparison of the overall survival of different treatment methods in patients with Muscle-invasive bladder cancer: A retrospective study.
    Urologia. 2024 Jun 12:3915603241256009. doi: 10.1177/03915603241256009.
    PubMed         Abstract available


    Urology

  52. YU J, Wang CG, Zhang Y, Yang W, et al
    A Novel Approach to Treatment with Antiangiogenic Agents in Adenocarcinoma of Urachal Origin.
    Urology. 2024;187:121-122.
    PubMed        

  53. BRANDT SB, Kingo PS, Laurberg JR, Lam GW, et al
    Reply to Editorial comments on "Definition of Benign Ureteroenteric Anastomotic Strictures in Ileal Conduits After Radical Cystectomy: Experience From a Single Center and Previously Published Literature".
    Urology. 2024;187:139.
    PubMed        

  54. BRANDT SB, Kingo PS, Laurberg JR, Lam GW, et al
    Definition of Benign Ureteroenteric Anastomotic Strictures in Ileal Conduits After Radical Cystectomy: Experience From a Single Center and Previously Published Literature.
    Urology. 2024;187:131-136.
    PubMed         Abstract available

  55. LIN JS, Zhao LC
    Editorial comments on "Definition of Benign Ureteroenteric Anastomotic Strictures in Ileal Conduits After Radical Cystectomy: Experience From a Single Center and Previously Published Literature".
    Urology. 2024;187:137-138.
    PubMed        

  56. MORAN M, Kim JE, Fu MZ, Ghodoussipour S, et al
    Worsening Neobladder Incontinence in a Patient on Nivolumab Therapy.
    Urology. 2024;187:92-93.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.